The Clinical Observation of First-Line Docetaxel and Carboplatin Treatment for Elderly Patients with Non-Selective Non-Small-Cell Lung Cancer

    Bao Ming-liang
    Studysummary This study found that first-line treatment with docetaxel and carboplatin was safe and effective for elderly patients with advanced non-selective non-small-cell lung cancer, showing an overall efficacy rate of 47.87%.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →